2020-Jul-14 at 07:19 pm
Preliminary second quarter 2020 reported revenue is expected to be approximately $1.83 billion, a decline of approximately 6% versus the 2019 period. Volume, measured by the number of requisitions, declined approximately 18% versus the prior year. Testing volumes in the company’s base business (excluding COVID-19 molecular and antibody testing) declined approximately 34% versus the prior year.
$DGX #Coronavirus #Testing #Loss #Bad